Effects of a Partially Supervised Conditioning Program in CF

Completed · Not applicable

Conditions studied: Cystic Fibrosis

In brief

Physical activity and exercise have become an accepted and valued component of Cystic Fibrosis care. Regular physical activity and exercise can slow the rate of decline of pulmonary function, improve physical fitness, and enhance quality of life. However, motivating people to be more active is challenging. Supervised exercise programs are expensive and labor intensive, and adherence falls off significantly once supervision ends. Unsupervised or partially supervised programs are less costly and more flexible, but compliance can be more problematic. The primary objective of this study is to evaluate the effects of a 12-months partially supervised exercise intervention along with regular motivation on forced expiratory volume in 1 second (FEV1) in a large international group of cystic fibrosis patients. Secondary endpoints include patient reported quality of life, as well as levels of anxiety and depression, and control of blood sugar. A total of 292 patients with cystic fibrosis 12 years and older with a FEV1 ≥35% predicted will be recruited. Following baseline assessments (2 visits) patients will be randomized into an intervention and a control group. Thereafter, they will be seen every 3 months for assessments in their centre for one year (4 follow-up visits). Along with individual counseling to increase vigorous physical activity by at least 3 hours per week on each clinic visit, the intervention group will document daily exercise and inactivity time and will receive a step counter and they will record their progress with a web-based program. They will also receive monthly phone calls from the study staff. After 6 months, they will continue with the step counter and web-based program for a further 6 months. The control group will receive access to this intervention after 12 months of standardized care. Should this relatively simple program prove successful, this will be made available on a wider scale internationally.

Key facts

Study ID

NCT01744561

Run by

Wuerzburg University Hospital

People needed

155

Starts

2014-07-01

Expected to finish

2018-10-15

Last updated by the study team

2018-10-22

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of Cystic Fibrosis
• Age ≥12 years
• Forced expiratory volume in 1 second (FEV1) ≥ 35% predicted
• Access to the internet

You may not qualify if…

• Participation in another clinical trial up to 4 weeks prior to the first baseline visit
• Pregnancy/Breastfeeding
• Inability to exercise
• More than 4 hours of reported strenuous physical activities per week currently or up to 3 months prior to baseline measurements and not already planned within the coming 6 months.
• Unstable condition precluding exercise (major hemoptysis or pneumothorax within the last 3 months, acute exacerbation and iv-antibiotics during the last 4 weeks, planned surgery, listed for lung transplantation, major musculoskeletal injuries such as fractures or sprains during the last 2 months, others according to the impression of the doctor)
• Cardiac arrhythmias with exercise
• Requiring additional oxygen with exercise
• Recent diagnosis of diabetes 3 months prior to screening or at screening
• Recent changes in medication 1 month or less prior to screening (systemic steroids, ibuprofen, inhaled antibiotics, mannitol, DNAse, hypertonic saline)
• At least one G551D mutation and not on ivacaftor (VX770) yet but planned start or planned stop of ivacaftor during the trial
• Colonization with Burkholderia cenocepacia

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania, United States
• Mukoviszidose-Ambulanz, Universitätsklinik für Kinder- und Jugendheilkunde, — Graz, Austria
• Cystische Fibrose Zentrum für Kinder, Jugendliche und Erwachsene — Innsbruck, Austria
• Montreal Children's Hospital, McGill University Health Centre - Glen Site — Monrtreal, Quebec, Canada
• Hôpital Renée Sabran, Service : Maladies respiratoires — Hyères, France
• Hôpital Calmette, Service Pneumologie-immuno-allergologie boulevard du Pr Leclercq — Lille, France
• Hôpital Jeanne de Flandre, Service: Pneumologie et allergologie pédiatriques — Lille, France
• Hôpital Arnaud de Villeneuve, Service: Maladies respiratoires — Montpellier, France
• Hôpital Necker, Service : Pneumologie et allergologie pédiatriques — Paris, France
• Hôpital Maison Blanche, Service : Maladies respiratoires — Reims, France
• Olgahospital, Klinikum Stuttgart — Stuttgart, Baden-Wurttemberg, Germany
• Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Tübingen — Tübingen, Baden-Wurttemberg, Germany
• Children´s Hospital of the University — Würzburg, Bavaria, Germany
• Pediatric Pulmonology and CF centre, Children´s Hospital, Ruhr University — Bochum, Germany
• Klinik und Poliklinik für Kinderheilkunde - Universitäts-Mukoviszidose-Centrum — Dresden, Germany
• Christiane Herzog CF-Zentrum, Goethe Universität — Frankfurt, Germany
• CF Zentrum Hamburg-Altona, Kinderarztpraxis Runge, Sextro,Held — Hamburg, Germany
• CF- Ambulanz, Kinderklinik, Pädiatrische Pneumologie, Allergologie und Neonatologie — Hanover, Germany
• Zentrum für Kinder- und Jugendmedizin, Pädiatrische Pneumologie, Allergologie und Mukoviszidose — Mainz, Germany
• Praxis für Lungen- und Bronchialheilkunde — Munich, Germany
• Klinik für Kinder- und Jugendmedizin / Universitätsklinikum — Münster, Germany
• University Medical Center, Child Development & Exercise Center, Wilhelmina Children's Hospital — Utrecht, Netherlands
• QuartierBleu, Praxis für Pneumologie am Lindenhofspital — Bern, Switzerland
• Inselspital, Universitätsklinik für Kinderheilkunde, Pneumologie — Bern, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.